A Phase III, multi-center, placebo–controlled trial of Sorafenib (BAY 43-9006) in patients with relapsed or refractory advanced predominantly non squamous Non-Small Cell Lung Cancer (NSCLC) after 2 or 3 previous treatment regimens.
Dr Ho, James Chung Man (Principal investigator)
Dr Wong King Yan Matthew (Co-Investigator)
Dr Wang Kwan Ling Julie (Co-Investigator)
Dr Lam Chung Mei Jamie (Co-Investigator)
Dr Lam Chi Leung David (Co-Investigator)
Non-small cell lung cancer, Sorafenib
Pharmaceutical Industry - General Award